ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

INCY: Incyte Genomics Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

INCYTE GENOMICS INC (NASD)
INCY	7.55	-0.17	(-2.20%)	Vol. 2,523,198	16:00 ET

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.

General Information

INCYTE CORP

Route 141 & Henry Clay Road Building E336 Wilmington, DE 19880 Phone: 302 498-6700 Fax: 302-425-2750 Web: www.incyte.com Email: pmurphy@incyte.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/17/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	7.72
52 Week High	8.32
52 Week Low	1.96
Beta	2.37
20 Day Moving Average	3,292,671.50
Target Price Consensus	9.94

% Price Change
4 Week	34.10
12 Week	11.69
YTD	99.21

% Price Change Relative to S&P 500
4 Week	32.66
12 Week	5.30
YTD	64.87

Share Information
Shares Outstanding (millions)	115.79
Market Capitalization (millions)	874.18
Short Ratio	3.03
Last Split Date	09/01/2000

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.38
Current Year EPS Consensus Estimate	-1.64
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	02/17/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.78
30 Days Ago	1.88
60 Days Ago	1.88
90 Days Ago	1.78

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	18.75%
vs. Previous Quarter	4.88%

Sales Growth
vs. Previous Year	-11.50%
vs. Previous Quarter:	19.01%

Price Ratios
Price/Book	-
Price/Cash Flow	-
Price / Sales	262.04

ROE
09/30/09	-
06/30/09	-
03/31/09	-

ROA
09/30/09	-85.95
06/30/09	-81.95
03/31/09	-80.23

Current Ratio
09/30/09	-
06/30/09	3.22
03/31/09	3.93

Quick Ratio
09/30/09	-
06/30/09	3.22
03/31/09	3.93

Operating Margin
09/30/09	-4,989.99
06/30/09	-5,010.73
03/31/09	-5,446.21

Net Margin
09/30/09	-
06/30/09	-5,010.70
03/31/09	-5,446.24

Pre-Tax Margin
09/30/09	-
06/30/09	-5,010.70
03/31/09	-5,446.24

Book Value
09/30/09	-
06/30/09	-2.99
03/31/09	-2.64

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	-
06/30/09	-1.38
03/31/09	-1.55

Debt to Capital
09/30/09	-
06/30/09	-
03/31/09	-


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research